Skip to main content
Retrospective TriNetX Network cohort study of adult PsA (N 123,031) pts, propensity- matched to non-PsA controls. PsA

Dr. John Cush RheumNow

6 months ago
Retrospective TriNetX Network cohort study of adult PsA (N 123,031) pts, propensity- matched to non-PsA controls. PsA had signif higher CV morbidity: MACE (HR 1.74); mortality (HR 1.95); CHF (HR 1.96), MI (HR 1.71), & CVA (HR 1.49). bDMARDs reduced MACE (HR 0.95) & mortality (HR https://t.co/bHrq9KpwBM
Economic analysis of ESR & CRP testing (are they same or different?). Compared to doing either ESR OR CRP, they foun

Dr. John Cush RheumNow

6 months ago
Economic analysis of ESR & CRP testing (are they same or different?). Compared to doing either ESR OR CRP, they found the ESR + CRP testing was cost-effective strategy, reducing misdiagnoses, followup costs and overall healthcare costs. https://t.co/UU15bxuPKP https://t.co/7zNkUOcQpU
phase 3 VALOR trial of 6-valent OspA-based Lyme dz vaccine (LB6V) vs placebo; 4 doses given @ Mos 0, 2, 5-9, & 12 m

Dr. John Cush RheumNow

6 months ago
phase 3 VALOR trial of 6-valent OspA-based Lyme dz vaccine (LB6V) vs placebo; 4 doses given @ Mos 0, 2, 5-9, & 12 mos later. LB6V reduced Lyme Dz risk by 73.2% @28d after 4th dose. But it was only 15.8% effective (falling short of prespecified 20%) because of fewer than expected https://t.co/TcX0GV05gY
Who Treats Spondyloarthritis Better?
  • MedPage Today
European nations may be winning at optimizing care for people with axial spondyloarthritis (axSpA), international survey data indicate. In data collected from physicians and patients in the U.S. and five European countries, American patients reported a greater symptom burden on average after treatment had begun, and they agreed less often with their physicians regarding satisfaction with therapy.
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Prevalence of fibromyalgia in PsA = 18%. FM-PsA pts have higher scores Dz activity scores from FM, rather than inflammat

Dr. John Cush RheumNow

6 months ago
Prevalence of fibromyalgia in PsA = 18%. FM-PsA pts have higher scores Dz activity scores from FM, rather than inflammation. Fibromyalgia is assoc w/ worse disease outcomes, including failure to achieve low disease activity state and poorer response to therapy. https://t.co/utQRXPmpDs
Missed #RheumNowLive 2026?

The full meeting is now available On Demand.

✔ 2 days of clinical updates
✔ Expert facu

Dr. John Cush RheumNow

6 months ago
Missed #RheumNowLive 2026? The full meeting is now available On Demand. ✔ 2 days of clinical updates ✔ Expert faculty panels ✔ Speaker slides ✔ Pre-learn modules Watch anytime for $250. Learn from the meeting that kicks off the year in rheumatology. 🔗 Access here: https://t.co/GJwap25PVU
Predictors of Response in Lupus

A systematic review suggests that traditional measures (serologies and disease activit

Dr. John Cush RheumNow

6 months 1 week ago
Predictors of Response in Lupus A systematic review suggests that traditional measures (serologies and disease activity) are superior to biomarkers in predicting response to biologics in systemic lupus erythematosus (SLE) patients. https://t.co/7YuYpoDctR https://t.co/J5VLrkDQ6G
Long-Term Bimekizumab Safety Data

Adverse effects from bimekizumab through 2 years or more of treatment for psoriatic

Dr. John Cush RheumNow

6 months 1 week ago
Long-Term Bimekizumab Safety Data Adverse effects from bimekizumab through 2 years or more of treatment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) were about as expected from shorter-term data, results from long-term extension studies indicated. https://t.co/AaJxewNQmQ
EULAR has updated its recommendations for the management of Behçet’s syndrome, the last being published in 2018. The current update carries no recommendations from the previous version: seven recommendations have content modifications, four have minor wording amends, and one is entirely new.
Rush University MDHAQ surveys done on 1,337 pts (excluding primary FM), identified 30% w/ anxiety, 24% depression, 25% f

Dr. John Cush RheumNow

6 months 1 week ago
Rush University MDHAQ surveys done on 1,337 pts (excluding primary FM), identified 30% w/ anxiety, 24% depression, 25% fibromyalgia, & 44% w any 3 of these. In this 44%, HIGHER pain (7 vs 4) and RAPID3 (17 vs 8.2) vs those without FM, anxiety, or depression (p< 0.001). https://t.co/GzZ0LZKPPR
Prednisone use in Alberta primary care 546 #RA pts - 40% of PCP RA Rx w/ 1 or more prednisone Rx. 41% Rx w/ both Pred +

Dr. John Cush RheumNow

6 months 1 week ago

Prednisone use in Alberta primary care 546 #RA pts - 40% of PCP RA Rx w/ 1 or more prednisone Rx. 41% Rx w/ both Pred + DMARD, w/ 44% on Pred median 124 day before DMARD. 66% continued Pred >1 yr after DMARD initiation. https://t.co/wrxQRP2TWN https://t.co/XxWpjafBsk

A retrospective cohort study of 195 renal Bx from 135 Lupus Nephritis pts, Mod-Severe interstitial fibrosis and tubular

Dr. John Cush RheumNow

6 months 1 week ago
A retrospective cohort study of 195 renal Bx from 135 Lupus Nephritis pts, Mod-Severe interstitial fibrosis and tubular atrophy (IFTA) strongly assoc w/non-renal response & ESRD progression (HR 8.9) (also w/ age, SLE duration, prior LN flares, higher chronicity index) https://t.co/3JGLi5R5Fs
RA pt on 7.5 mg/d Prednisone need hip replacement. What do you advise re: pred dose before TKR?

Dr. John Cush RheumNow

6 months 1 week ago
RA pt on 7.5 mg/d Prednisone need hip replacement. What do you advise re: pred dose before TKR?
×